- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT03518372
Myocardial Injury and Intraoperative Tissue Oximetry in Patients Undergoing Spine Surgery (MONITOR)
Myocardial Injury and Intraoperative Tissue Oximetry in Patients Undergoing Spine Surgery (MONITOR)
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Significance:
Each year 10 million people worldwide suffer from myocardial injury after non-cardiac surgery (MINS). The majority of these events are undetected because they are asymptomatic and there is sparse knowledge about triggering causes. Major surgery is associated with a high risk of postoperative complications. These include covert stroke, myocardial injury and -infarction, and are all major contributors to mortality. The 30-day post-operative mortality in patients suffering from covert stroke is increased up to eight-fold compared with matched controls and is 10% in patients with MINS, which makes it a substantial public health problem. Approximately 33% of patients undergoing major spine surgery suffer from major postoperative complications, including stroke and myocardial infarction. However, knowledge is lacking regarding which perioperative factors predict myocardial injury and -infarction, covert and overt stroke, and mortality in high-risk patients such as those undergoing major spine surgery.
Measure of tissue oxygenation with near-infrared spectroscopy (NIRS) is non-invasive and uncomplicated. Tissue desaturation is common in spine surgery patients. Previous studies found that a decrease in tissue oxygenation (StO2) was associated with postoperative complications such as creatinine elevation, hypotension and prolonged hospitalization. However, current knowledge of how tissue oxygenation affects other clinical outcomes is lacking.
Thus, to address these knowledge gaps the investigators propose a cohort study to examine the association between tissue oxygenation and MINS in patients undergoing major spine surgery.
Methods This is a prospective observational cohort study. Participants are patients undergoing major spine surgery. Measurements include blood samples, non-invasive tissue oximetry and collection of general perioperative factors from the anesthesia machine. First measurements are made on the day of surgery and further measurements are conducted on the first two postoperative days. Secondary outcomes from medical records (e.g. 30-day mortality) are collected retrospectively.
Patients will be screened from Operation Room Surgery Schedule at University of California, San Francisco (UCSF) prior to surgery. The informed consent will be obtained at the preoperative area about 30-60 min prior to surgery. Eligible patients will sign a written consent form and HIPAA Authorization for study participation. If the subject is determined to have diminished or lack a capacity to consent, a surrogate/legally authorized representative will need to be present to authorize their participation in the study and complete the applicable forms as required by UCSF and Californian law.
Data from medical records are entered by certified study personnel into REDCap (a HIPAA compliant online data collection tool) to assure all data is complete and stored correctly. Included in REDCap is a data dictionary with descriptions of every individual variable. Standard Operating Procedures (SOP's) for patient recruitment and enrollment, data collection and data extraction have been created and are available. Tissue Oximetry data is collected separately with the laboratory's oximeters. After each case/study the data is uploaded to an online secure box. As all data are collected case-by-case in the course of the study, all missing data are registered immediately as missing in REDCap and will be treated as missing data in the final data analysis.
Sample size:
The sample size assessment is based on previous studies investigation tissue oximetry and clinical outcomes.
Effect size: 0.36 (SD=0.50) based on Meng et al. (Br J Anaesth. 2017 Apr 1;118(4):551-562. doi: 10.1093/bja/aex008.):
Muscle tissue oxygenation (SmO2) time weighted area under the curve (AUC) (%*min*hr-1 (SD)):
<3 complications: 1.4 (0.8) >3 complications: 1.9 (1.2) p-value: 0.07 Proportion of patients with >3 composite complications = 33% Alpha: 0.05 Beta: 0.2 (power=0.8) Sample size: 68. We expect to include 70 patients in this study.
By convention the 5% level of alpha and 20% level of beta have been used. As this study is explorative and hypothesis-testing, the investigators consider the above calculation to contain sufficient information.
Statistical analysis:
Primary analysis will be multiple regression with adjustment for age, sex and pre-existing conditions including cardiovascular disease, coronary heart disease, heart failure, diabetes mellitus and obstructive respiratory diseases. The following pre-specified potential confounders will be tested separately: age, gender, BMI, smoking status, history of coronary artery disease, congestive heart failure, stroke, transient ischemic attacks, chronic obstructive pulmonary disease, insulin therapy, hypertension, preoperative creatinine elevation above normal, and length of surgery. Since this relationship may or may not be linear, the data will first visually be assessed by plotting the estimated probability (on the logit scale) of having the outcome as a function of StO2, using a univariable logistic regression incorporating a smooth (thin-plate regression spline) term for StO2 (smoothing parameter obtained via cross-validation). The fit of each model will be assessed by the Hosmer-Lemeshow goodness-of-fit test. STATA software will be used for the statistical procedures.
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
California
-
San Francisco, California, États-Unis, 94143
- UCSF Medical Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Male or female ≥18 years
- Patient is undergoing elective surgery of the spine
- Surgery is scheduled to last ≥ 2 hours and involve instrumentation
Exclusion Criteria:
- Patient is < 18 years
- Patient is undergoing emergent or urgent surgery
- American Society of Anesthesiologist (ASA) status > IV
- Patient is undergoing non-instrumental surgery, such as laminectomy alone
- Patient is undergoing spine surgery for tumor or infection
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
High-sensitivity Troponin T elevation
Délai: Measurement done on first and second day after surgery (highest value of the two is used in the primary analysis)
|
Peak value (the highest of two postoperative measurements) of high-sensitivity Troponin T (hsTnT) elevation (as assessment for myocardial injury).
|
Measurement done on first and second day after surgery (highest value of the two is used in the primary analysis)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Myocardial injury after non-cardiac surgery (MINS)
Délai: Baseline prior to surgery (for adjustment), first and second day after surgery.
|
Myocardial injury after non-cardiac surgery (MINS) assessed as a at least one postoperative hsTnT value of 14 ng/L or more.
Two independent expert adjudicators will screen medical records for patients with troponin elevations for non-ischemic etiology of the elevation (e.g.
sepsis or kidney failure).
|
Baseline prior to surgery (for adjustment), first and second day after surgery.
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Myocardial infarction
Délai: Within 30 days after surgery
|
Diagnosis of myocardial infarction from medical record
|
Within 30 days after surgery
|
|
Non-fatal cardiac arrest
Délai: Within 30 days after surgery
|
Diagnosis of non-fatal cardiac arrest from medical record
|
Within 30 days after surgery
|
|
Transient cerebral ischemia (TCI)
Délai: Within 30 days after surgery
|
Diagnosis of transient cerebral ischemia from medical record
|
Within 30 days after surgery
|
|
Overt stroke
Délai: Within 30 days after surgery
|
Diagnosis of overt stroke from medical record
|
Within 30 days after surgery
|
|
Mortality
Délai: Within 30 days after surgery
|
From medical record
|
Within 30 days after surgery
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Phil Bickler, MD PhD, University of California, San Francisco
Publications et liens utiles
Publications générales
- Meng L, Xiao J, Gudelunas K, Yu Z, Zhong Z, Hu X. Association of intraoperative cerebral and muscular tissue oxygen saturation with postoperative complications and length of hospital stay after major spine surgery: an observational study. Br J Anaesth. 2017 Apr 1;118(4):551-562. doi: 10.1093/bja/aex008.
- Bernholm KF, Meyhoff CS, Bickler P. Association between tissue oxygenation and myocardial injury in patients undergoing major spine surgery: a prospective cohort study. BMJ Open. 2021 Sep 17;11(9):e044342. doi: 10.1136/bmjopen-2020-044342.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- Tissue Oximetry and Troponin
- IRB#14-12996 (Autre identifiant: Institutional Review Board)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .